Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program

Ascierto, Paolo A.; Simeone, Ester; Chiarion-Sileni, Vanna; Vecchio, Michele Del; Marchetti, Paolo; Cappellini, Gian Carlo Antonini; Ridolfi, Ruggero; Rosa, Francesco De; Cognetti, Francesco; Ferraresi, Virginia; Testori, Alessandro; Queirolo, Paola; Bernengo, Maria Grazia; Guida, Michele; Galli, Luca; Mandalà, Mario; Cimminiello, Carolina; Rinaldi, Gaetana; Carnevale-Schianca, Fabrizio; Maio, Michele

doi:10.3109/07357907.2014.885984

Cited by 91 publications

(61 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A paucity of robust data on the outcomes of patients treated with immunotherapy following BRAF-targeted therapy limits our understanding of this issue; however, small series and genomic studies of immunotherapy resistance suggest that resistance to BRAF inhibition might attenuate, rather than augment, the benefit of immunotherapy [165][166][167] .…”

Section: Response Criteriamentioning

confidence: 99%

Targeted agents and immunotherapies: optimizing outcomes in melanoma

et al. 2017

View full text Add to dashboard Cite

Section: Response Criteriamentioning

confidence: 99%

Targeted agents and immunotherapies: optimizing outcomes in melanoma

et al. 2017

View full text Add to dashboard Cite

“…With this success have come a few challenges, such as optimal treatment sequencing and combination therapy. In patients with BRAF mutations, retrospective data support a strategy of first-line immunotherapy followed by BRAF-targeted therapy, if needed, and standard BRAF-targeted therapy should be combined BRAF-MEK inhibitor therapy on the heels of three randomized phase III trials showing superiority of combination therapy compared with single-agent BRAF inhibitor therapy (11)(12)(13)(14)(15)(16). Finally, the initial data for combined immunotherapy are very encouraging, particularly with the regimen of concurrent ipilimumab and nivolumab (16).…”

Section: Introductionmentioning

confidence: 99%

New Strategies in Melanoma: Entering the Era of Combinatorial Therapy

Sullivan

Flaherty

2015

Clinical Cancer Research

View full text Add to dashboard Cite

The treatment of metastatic melanoma has been revolutionized over the past decade as effective molecularly targeted therapies and immunotherapies entered the clinic. It is hoped that deeper insights into the characteristics of patients and tumors that are most responsive will allow more precise patient selection for these therapies while understanding mechanisms of resistance will facilitate the develop of rational combinations or next-generation agents aimed at novel targets. Clin Cancer Res; 21(11); 2424-35. Ó2015 AACR. Disclosure of Potential Conflicts of InterestR.J. Sullivan is a consultant/advisory board member for Astex Pharmaceuticals. K.T. Flaherty is a consultant/advisory board member for GlaxoSmithKline, Novartis, and Roche. No other potential conflicts of interest were disclosed. Editor's DisclosuresThe following editor(s) reported relevant financial relationships: J.L. Abbruzzese is a consultant/advisory board member for Celgene and Halozyme. CME Staff Planners' DisclosuresThe members of the planning committee have no real or apparent conflict of interest to disclose. Learning ObjectivesUpon completion of this activity, the participant should have an improved understanding of the standard treatment options for advanced (metastatic and unresectable) melanoma and the rationale for building "regimens" such as dual BRAF/MEK inhibitor therapy, combined immunotherapy (e.g., ipilimumab plus nivolumab), and the combination of molecular and immune-targeted therapy.

show abstract

“…Some data indicate that the sequencing of BRAF inhibitors and ipilimumab has a marked effect on the efficacy and tolerability of the combination in patients with BRAFmutant melanoma, and indicate that the drugs should be sequenced (78)(79)(80). Data from a recent retrospective analysis of a cohort of patients treated with immunotherapy and then a BRAF inhibitor (with or without a MEK inhibitor) showed prior immunotherapy did not appear to have an adverse effect on response to a BRAF inhibitor.…”

Section: Clinical Experience and Considerations In Combining Novel Immentioning

confidence: 99%

Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects

Antonia

Larkin

Ascierto

2014

Clinical Cancer Research

View full text Add to dashboard Cite

Immuno-oncology is an evolving treatment modality that includes immunotherapies designed to harness the patient's own immune system. This approach is being studied for its potential to improve long-term survival across multiple tumor types. It is now important to determine how immunotherapies may be most effectively used to achieve the best possible patient outcomes. Combining or sequencing immunotherapies that target distinct immune pathways is a logical approach, with the potential to further enhance the magnitude of the antitumor immune response over single agents. Early clinical data in patients with melanoma treated with two immune checkpoint inhibitors, ipilimumab and nivolumab, suggest support for this combination approach. Numerous other combination approaches are being evaluated in early-phase clinical trials; however, their clinical activity remains unknown. Clinical experience to date has shown that when combining an immuno-oncology agent with an existing therapeutic modality, it is important to determine the optimal dose, schedule, and sequence. Clin Cancer Res; 20(24); 6258-68. Ó2014 AACR.

show abstract

Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program

Cited by 91 publications

References 19 publications

Targeted agents and immunotherapies: optimizing outcomes in melanoma

Targeted agents and immunotherapies: optimizing outcomes in melanoma

New Strategies in Melanoma: Entering the Era of Combinatorial Therapy

Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects

Contact Info

Product

Resources

About